DHILLON PUNIT 4

What Happened
Punit Dhillon, Chief Executive Officer of Skye Bioscience, received an award of 280,000 derivative securities (stock options) on February 6, 2026. The Form 4 reports an acquisition price of $0.00 (no cash paid at grant). This was an award/grant (transaction code A), not a market purchase or sale.

Key Details

• Transaction date: 2026-02-06; Form 4 filed: 2026-02-09 (filed within the SEC’s two-business-day window).
• Award: 280,000 stock options (reported as derivative securities) at $0.00 per share.
• Shares/ownership after transaction: Not disclosed in the supplied filing details.
• Footnote: The stock option vests in equal monthly installments over a four-year period beginning January 19, 2026.
• Transaction type: A = Award/Grant (not an immediate exercise or sale).

Context
This filing documents an option grant (a common form of executive compensation). These options will vest over time and must typically be exercised to become actual shares; the grant itself does not represent an immediate sale or cash proceeds. No speculative conclusions about the CEO’s market view should be drawn from a routine compensation award.